Overview
- A team led by Dieter Egli posted a bioRxiv preprint on June 1 reporting targeted base edits in early human embryos, claiming this is the first application of base editing in embryos.
- Base editing is a CRISPR-derived method developed by David Liu that swaps single DNA letters without cutting both DNA strands, and the study targeted genes including PCSK9 and HBG.
- The authors report many embryos contained the intended edits but also showed mosaicism, meaning some cells were edited and others were not.
- Researchers say the method produced fewer large deletions and chromosomal abnormalities than earlier CRISPR-only embryo studies, but they and outside scientists note off-target changes and long-term effects remain unresolved.
- The paper has not been peer reviewed, the lead authors say the work is not ready for clinical use, and the result has prompted calls for careful validation, public discussion, and regulatory oversight before any move toward heritable clinical applications.